[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630847":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":44,"collaborators":10,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":73,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Air Liquide Healthcare Spain","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"AHCL-IQ Home-based Cohort",null,"Adults with type 1 diabetes initiating the advanced hybrid closed-loop system (Tandem Control-IQ) in a home-based setting",[13],{"name":14,"affiliation":15,"role":16},"Georgios Kyriakos","Hospital General Universitario Santa Lucía, Cartagena","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"María Martínez Mateos","CONTACT","+34 690 283 723","maria.martinez-mateos@airliquide.com",{"name":24,"role":20,"phone":10,"phoneExt":25,"email":26},"Carla Yago-Díez","+34 667 149 95","carla.yagodiez@airliquide.com",[28],{"facility":29,"status":10,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hospital General Universitario Santa Lucía","Cartagena","Murcia","30202","Spain",{"type":35,"coordinates":36},"Point",[37,38],-0.98397,37.60197,{"lat":38,"lon":37},[41],{"name":14,"role":20,"phone":42,"phoneExt":10,"email":43},"+34 968 12 86 00","georgios.kyriakos@carm.es",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100630847",false,"NCT07492992","HOME-AHCL: Home-Based Implementation of an Advanced Hybrid Closed-Loop System With Telemonitoring in Type 1 Diabetes","Safety, Effectiveness, Quality of Life, Costs, and Efficiency of the Home Setup of the Hybrid Closed-Loop System in People With Type 1 Diabetes: Application of a Value-Based Diabetes Management Model","HOME-AHCL","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes.\n* Aged 18 years or older.\n* Candidate to initiate an Advanced Hybrid Closed-Loop (AHCL) system based on standard clinical criteria.\n* Access to the internet and\u002For a compatible smartphone to connect to the system.\n* Willingness to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Currently participating in another diabetes-related clinical trial.\n* Pregnant or planning to become pregnant during the study.\n* Inability to use the system autonomously (e.g., severe cognitive impairment or severe psychiatric disorders without support).\n* Medical contraindication for the use of insulin pumps or continuous glucose monitors (CGM).","ALL","18 Years",{"count":56,"type":57},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate a new home-based setup and care model for an advanced hybrid closed-loop insulin pump system (Tandem with Control-IQ). The study will look at the safety, effectiveness, costs, and impact on quality of life in adults with type 1 diabetes.\n\nThe main questions it aims to answer are:\n\n* Is it safe for participants to start using the insulin pump system at home instead of the hospital? (Measured by the amount of time blood sugar is very low, under 54 mg\u002FdL).\n* Does this home-based care model help participants keep their blood sugar in a healthy range?\n* How does this model affect the participants' quality of life, device satisfaction, and overall experience?\n* Does this model reduce healthcare costs and the need for hospital visits?\n\nParticipants will:\n\n* Complete an online technical training course before the setup.\n* Receive a home visit from a specialized nurse to configure and start the insulin pump system.\n* Have their device data monitored remotely every 14 days by the nursing team to manage any health alerts.\n* Attend scheduled clinical follow-up visits at 1, 3, 6, and 12 months.\n* Answer surveys about their quality of life, their experience with the healthcare service, and their satisfaction with the new device.",[61],"Diabetes Mellitus Type 1",[63,64,65,66,67,68,69,70,71,72],"Type 1 Diabetes","Advanced Hybrid Closed Loop","Insulin Pump","Continuous Glucose Monitoring","Telemonitoring","Remote Patient Monitoring","Value-Based Healthcare","Home Care Services","Quality of Life","Cost-Effectiveness","NOT_YET_RECRUITING","2026-04-07",{"date":76,"type":77},"2026-04-13","ACTUAL",{"date":79,"type":57},"2026-04",{"date":81,"type":57},"2028-04",{"name":5,"class":6},1]